ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2479

Rheumatoid Arthritis Does Not Increase Risk of Short Term Total Knee Replacement (TKR) Adverse Events (AE)

Zachary J. LoVerde1, Lisa A. Mandl2, Beverly K. Johnson2, Mark P. Figgie3, Friedrich Boettner4 and Susan M. Goodman2, 1New York Medical College, Valhalla, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Orthopedics, Hospital for Special Surgery, New York, NY, 4Orthopaedics, Hospital for Special Surgery, New York, NY

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Adverse events, Knee, Osteoarthritis, rheumatoid arthritis (RA) and total joint replacement

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects IV: Non-biologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events

Session Type: Abstract Submissions (ACR)

Background/Purpose: TKR is commonly performed for rheumatoid arthritis (RA) and osteoarthritis (OA). Historically, RA patients were at higher risk of post-operative AEs. The purpose of this study was to evaluate whether this is true in the era of widespread DMARD and biologic use.

Methods: Patients participating in the institution’s TKR registry between 2007 and 2010 were screened for RA by ICD-9 code or self report, and the diagnosis confirmed by chart review. AEs were identified by 6 month questionnaire, and review of office and hospital notes. Self-reported AEs were validated by chart review or phone call. Infection was defined as any surgical site infection as well as systemic infections. Each RA patient was matched to 2 controls by age (+/- 5 years), gender, and primary vs. revision surgery. Baseline characteristics of RA and OA patients were compared by standard statistics and bivariate relationships to AE calculated.

Results: 159 RA TKA patients were identified, and matched to 318 OA controls. Mean age: 63 years (range 22-93), 88% female. 20% of RA were on corticosteroids, and 67% were on DMARDS. Assessment of co-morbidities using Charlson co-morbidity scores did not reveal a significant difference between groups. RA had significantly worse baseline WOMAC pain (47.1 vs. 53.7; p-value < 0.01) and function scores (43.8 vs. 54.2; p-value < 0.01), and lower perceived health status on the EQ-5D (0.59 vs. 0.65; p-value < 0.01), and SF-36 PCS (29.3 vs. 33.3; p-value < 0.01). Operative time (144 minutes RA vs. 146 minutes OA; p-value = 0.66) and length of stay (5 days for both) were no different between groups. There were no deep joint infections in either group, and there was no significant difference between OA and RA rates of superficial infection, i.e. cellulitis or stitch abscesses (9.4% RA vs. 10.1%; p-value = 0.82) or thromboembolism (1.3% RA vs. 0.6%; p-value = 0.60). Re-operation was more common in OA (2.5% vs. 8.8% p-value = .015), largely due to manipulations. 

Conclusion: The belief that RA increases post-operative AEs may be outdated. In spite of worse pre-operative function, and high steroid and DMARD use, infection and wound healing complications were not increased in RA in a high volume orthopedic hospital. RA patients additionally had lower rates of re-operation. These data are reassuring, but further study is needed to see if these trends continue and are generalizable.

Adverse Events

RA cases (N=159)

OA controls (N=318)

P-Value

In hospital (post-op, prior to discharge)

 

 

 

Surgical Site Infection (SSI), N (%)

2 (1.3%)

3 (0.9%)

0.99

Other infection, N (%)

2 (1.3%)

7 (2.2%)

0.72

DVT, N (%)

1 (0.6%)

4 (1.3%)

0.67

PE, N (%)

0

1 (0.3%)

0.99

Pneumonia, N (%)

1 (0.6%)

1 (0.3%)

0.99

In office (post-op, within 6 months)

 

 

 

SSI, N (%)

6 (3.8%)

19 (6.0%)

0.39

Other infection, N (%)

3 (1.9%)

4 (1.3%)

0.69

DVT, N (%)

0

1 (0.3%)

0.99

PE, N (%)

1 (0.6%)

1 (0.3%)

0.99

Pneumonia, N (%)

0

0

—

REOP, N (%)

4 (2.5%)

28 (8.8%)

0.02

REOP manipulation

2 (1.3%)

25 (7.9%)

<0.01

REOP revision

1 (0.6%)

3 (0.9%)

0.99

REOP other

1 (0.6%)

0

0.33

Self-report (at 6 months)

 

 

 

Infection, N (%)

1 (0.72%)

6 (2.0%)

0.44

DVT, N (%)

0

8 (2.6%)

0.06

PE, N (%)

1 (0.72%)

1 (0.3%)

0.52

Pneumonia, N (%)

2 (1.5%)

1 (0.3%)

0.23

6-month Totals*

 

 

 

Infection (SSI and other Infection), N (%)

15 (9.4%)

32 (10.1%)

0.83

DVT, N (%)

1 (0.6%)

10 (3.1%)

0.11

PE, N (%)

2 (1.3%)

2 (0.6%)

0.60

Pneumonia, N (%)

3 (1.9%)

2 (0.6%)

0.34

REOP (manipulation, revision, and other), N (%)

4 (2.5%)

28 (8.8%)

0.02

*The same AE identified by multiple sources was counted only once


Disclosure:

Z. J. LoVerde,
None;

L. A. Mandl,
None;

B. K. Johnson,
None;

M. P. Figgie,
None;

F. Boettner,
None;

S. M. Goodman,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2012

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-does-not-increase-risk-of-short-term-total-knee-replacement-tkr-adverse-events-ae/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology